Obeticholic acid and other FXR agonists have been investigated for NAFLD/NASH across several clinical trials, with modestly improved liver histology and biochemistry, although with significant side effects including drug-induced liver toxicity, dyslipidemia, and severe pruritis that have limited further development for this indication44. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.